The novel TRAIL-receptor agonist APG350 exerts superior therapeutic activity in pancreatic cancer cells

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has raised attention as a novel anticancer therapeutic as it induces apoptosis preferentially in tumor cells. However, first-generation TRAIL-receptor agonists (TRAs), comprising recombinant TRAIL and agonistic receptor-specific antibod...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Cell Death Dis
Main Authors: Legler, Karen, Hauser, Charlotte, Egberts, Jan-Hendrik, Willms, Anna, Heneweer, Carola, Boretius, Susann, Röcken, Christoph, Glüer, Claus-Christian, Becker, Thomas, Kluge, Michael, Hill, Oliver, Gieffers, Christian, Fricke, Harald, Kalthoff, Holger, Lemke, Johannes, Trauzold, Anna
Format: Artigo
Jezik:Inglês
Izdano: Nature Publishing Group UK 2018
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5906476/
https://ncbi.nlm.nih.gov/pubmed/29670075
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41419-018-0478-0
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki